NRAS mutation in differentiated thyroid cancer
暂无分享,去创建一个
K. Prabhash | V. Noronha | P. Chandrani | V. Patil | A. Chougule | N. Menon | A. Joshi | N. Mittal | O. Shetty | Ajay Singh | S. Saha
[1] C. Berking,et al. Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] V. Marotta,et al. Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer , 2021, Cancers.
[3] S. Nissar,et al. RAS mutations and colorectal cancer: Testing and precision medicine , 2021 .
[4] K. Chatterjee,et al. Extended RAS mutations (KRAS and NRAS) in patients with colorectal cancers in eastern India: An observational study , 2021 .
[5] J. Klubo-Gwiezdzinska,et al. Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review , 2020, Cancers.
[6] C. Garbe,et al. Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover , 2020, Cancers.
[7] B. Solomon,et al. Mitogen-activated protein kinase pathway inhibition for re-differentiation of radioiodine-refractory differentiated thyroid cancer: an evolving protocol. , 2019, Thyroid : official journal of the American Thyroid Association.
[8] M. Hidalgo,et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours , 2018, British Journal of Cancer.
[9] D. Schadendorf,et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.
[10] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[11] AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.
[12] M. Nikiforova,et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. , 2015, Annals of surgery.
[13] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[14] J. Desai,et al. A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. , 2014 .
[15] V. D. Di Crescenzo,et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.
[16] K. Flaherty,et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[17] V. Sondak,et al. Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) , 2012, Clinical Cancer Research.
[18] J. Settleman,et al. Isoform-specific ras functions in development and cancer. , 2009, Future oncology.
[19] L. Chow,et al. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors , 2008, Cancer Chemotherapy and Pharmacology.
[20] E. Kaplan,et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. , 1994, Surgery.
[21] N. Lemoine,et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. , 1989, Oncogene.
[22] L. Old,et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? , 1984, Nature.
[23] C. Marshall,et al. A transforming gene present in human sarcoma cell lines , 1982, Nature.